Inhibition of influenza M2-induced cell death alleviates its negative contribution to vaccination efficiency

PLoS ONE

Volumn 3, Issue 1, 2008, Pages

  Ilyinskii, Petr O ^a   Gambaryan, Alexandra S ^b   Meriin, Anatoli B ^c   Gabai, Vladimir ^c   Kartashov, Alex ^d   Thoidis, Galini ^a   Shneider, Alexander M ^a  

^a Cure Lab   (United States)

^b CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Policy Analysis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HYBRID PROTEIN; INFLUENZA VACCINE; NONSTRUCTURAL PROTEIN 1; PROTEIN M1; PROTEIN M2; PROTEIN NP; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA IMMUNIZATION; DRUG EFFICACY; GENE CONSTRUCT; GENE SEQUENCE; GENETIC CONSERVATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SEQUENCE ANALYSIS; VIRUS INHIBITION; VIRUS STRAIN; ANIMAL; CELL LINE; IMMUNOLOGY; ORTHOMYXOVIRUS; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; PLASMID; WESTERN BLOTTING;

MAMMALIA; ORTHOMYXOVIRIDAE;

ANIMALS; BLOTTING, WESTERN; CELL DEATH; CELL LINE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS;

EID: 39049150770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001417     Document Type: Article

References (15)

1. Pinto LH, Lamb RA (2007) Controlling influenza virus replication by inhibiting its proton channel. Mol Biosyst 3: 18-23.
2. Zebedee S, Lamb RA (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62: 2762-2772.
3. Tompkins S, Zhao ZS, Lo CY, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426-435.
4. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, et al. (2007) Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 3: 157-164.
5. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, et al. (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13: 1399-1402.
6. Heinen P, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT (2002) Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 83: 1851-1859.
7. Ilyinskii P, Gabai VL, Sunyaev SR, Thoidis G, Shneider AM (2007) Toxicity of Influenza A Virus Matrix Protein 2 for Mammalian Cells is Associated with its Intrinsic Proton-Channeling Activity. Cell Cycle 6;in press.
8. Schroeder C, Heider H, Moncke-Buchner E, Lin TI (2005) The influenza virus ion channel and maturation cofactor M2 is a cholesterol-binding protein. Eur Biophys J 34: 52-66.
9. Zhirnov O, Isaeva EI, Konakova TE, Thoidis G, Piskareva LM, et al. (2007) Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza and Other Respiratory Viruses 1: 71-79.
10. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
11. Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, et al. (2006) Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol 151: 921 931.
12. Gitelman AK, Kaverin NV, Kharitonenkov IG, Rudneva IA, Zhdanov VM (1984) Changes in the antigenic specificity of influenza hemagglutinin in the course of adaptation to mice. Virology 134: 230-232.
13. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W (2004) A "universal" human influenza A vaccine. Virus Research 103: 173-176.
14. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, et al. (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337: 149-161.
15. De Filette M, Fiers W, Martens W, Birkett A, Ramne A, et al. (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24: 6597-6601.